Walleye Capital
AVTX icon

Walleye Capital’s Avalo Therapeutics AVTX Stock Holding History

Walleye Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Buy
+185,613
New +$2.93M 0.01% 1078
2026
Q1 		– Sell
-41,693
Closed -$757K – 4381
2025
Q4 		$757K Sell
41,693
-3,050
-7% -$51.5K ﹤0.01% 2648
2025
Q3 		$569K Buy
44,743
+24,130
+117% +$208K ﹤0.01% 2509
2025
Q2 		$103K Buy
20,613
+390
+2% +$1.82K ﹤0.01% 3765
2025
Q1 		$162K Buy
20,223
+746
+4% +$5.65K ﹤0.01% 3403
2024
Q4 		$145K Buy
+19,477
New +$208K ﹤0.01% 3947

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Walleye Capital's AVTX Position: Q2 2026 in Review

Walleye Capital opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 185,613 shares worth $3.43M. The stake represents 0.01% of the portfolio and ranks #1078 among its holdings. This is a return to the name: Walleye Capital previously reported a position in AVTX as recently as Q4 2025.

Walleye Capital first reported a position in AVTX in Q4 2024 and has held it in 6 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Walleye Capital held 185,613 shares of Avalo Therapeutics worth $3.43M as of Q2 2026.
  • Avalo Therapeutics was a new Walleye Capital position in Q2 2026.
  • Avalo Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1078 holding.
  • Walleye Capital first reported a position in Avalo Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.